文献速递核素与放射性配体治疗

II期试验证明基于剂量学的个体化177Lu-DOTATATE治疗NET患者的疗效与安全性

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-04-22

这项II期试验评估了基于肾脏剂量学调整周期数的个体化177Lu-DOTATATE治疗,纳入96例进展期、生长抑素受体阳性、Ki 67标记指数<20%的神经内分泌肿瘤患者,每周期7.4 GBq、间隔10±2周,直至达到预设肾脏辐射剂量。客观肿瘤缓解为16%部分缓解、66%疾病稳定、19%疾病进展,中位无进展生存期29个月、总生存期47个月,总体毒性轻微,3-4级毒性<10%且以血液学为主,无3-4级肾脏毒性。

要点

  • 个体化177Lu-DOTATATE基于肾脏剂量学调整周期数,中位5周期(范围1-9),客观缓解16%部分缓解、66%疾病稳定。
  • 中位无进展生存期29个月、总生存期47个月,且与肾脏剂量、体能状态和Ki 67水平显著相关,与肿瘤起源无关。
  • 总体毒性轻微,3-4级毒性<10%且以血液学为主,无3-4级肾脏毒性。

核心结论

  • 基于肾脏剂量学的个体化177Lu-DOTATATE治疗明显可行、毒性低且疗效有前景,显示出超越标准方案的潜力,并应在随机试验中进一步评估。

研究设计与样本

  • II期试验,纳入进展期、生长抑素受体阳性、Ki 67标记指数<20%的神经内分泌肿瘤患者。
  • 患者接受7.4 GBq 177Lu-DOTATATE,间隔10±2周,直至达到预设肾脏辐射剂量。
  • 主要终点为客观肿瘤缓解(RECIST v 1.1),次要终点包括无进展生存期、总生存期和毒性(CTCAE v. 4.0)。
  • 96例患者可评估疗效,接受中位5周期(范围1-9)治疗。

主要发现

  • 客观肿瘤缓解为16%部分缓解、66%疾病稳定、19%疾病进展。
  • 中位无进展生存期为29个月,中位总生存期为47个月。
  • 无进展生存期和总生存期与肾脏剂量、体能状态和Ki 67水平显著相关,与肿瘤起源无关。
  • 总体毒性轻微,最常见为1-2级贫血、血小板减少、乏力、恶心和腹泻。
  • 3-4级毒性发生率<10%,主要为血液学毒性,无3-4级肾脏毒性。

关键数值与推荐

  • 个体化方案:每周期7.4 GBq 177Lu-DOTATATE,间隔10±2周,周期数依据肾脏剂量学调整,中位5周期(范围1-9)。
  • 入组标准包括进展期、生长抑素受体阳性神经内分泌肿瘤且Ki 67标记指数<20%。
  • 疗效评价采用RECIST v 1.1,毒性评价采用CTCAE v. 4.0。

临床怎么用

  • 作者认为基于肾脏剂量学的个体化177Lu-DOTATATE治疗可行、毒性低且疗效有前景,并建议在随机试验中进一步评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radionuclide therapy with 177Lu-DOTATATE is well established for patients with advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule of 7.4 GBq at four occasions. However, this approach does not consider individual variability affecting the tumor radiation dose or dose to organs at risk. Therefore, it is important to assess more personalized strategies. The aim of this phase II trial was to evaluate individualized 177Lu-DOTATATE for which the number of cycles varied based on renal dosimetry. METHODS: Patients were eligible if they had a progressive, somatostatin receptor-positive neuroendocrine tumor with a Ki 67 labeling index < 20%. They received cycles of 7.4 GBq of 177Lu-DOTATATE at 10 ± 2-week intervals until a predefined radiation dose to the kidneys was reached. The primary endpoint was objective tumor response (RECIST v 1.1). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity (CTCAE v. 4.0). RESULTS: Ninety-six patients who had received a median of 5 cycles (range 1-9) were evaluable for efficacy. The objective tumor response was 16% partial response, 66% stable disease, and 19% progressive disease. The median PFS and OS were 29 months and 47 months, respectively, and were significantly associated with kidney dose, performance status, and Ki 67 levels but not with tumor origin. The overall toxicity was mild, and the most common events were grade 1-2 anemia, thrombocytopenia, fatigue, nausea, and diarrhea. Grade 3-4 toxicity occurred in < 10% of patients and was mostly hematological, with no grade 3-4 renal toxicity. CONCLUSION: Individualized treatment with 177Lu-DOTATATE based on renal dosimetry is clearly feasible with low toxicity and promising efficacy, showing the potential to further improve outcome beyond the standard approach, and should be further assessed in randomized trials. TRIAL REGISTRATION: EudraCT 2011-000,240-16. NCT01456078. https://clinicaltrials.gov/ct2/show/NCT01456078.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sundlöv A, Gleisner KS, Tennvall J, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022. PMID: 35451612. doi:10.1007/s00259-022-05786-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。